Accuray's CyberKnife VSI System Named Best New Radiology Device

SUNNYVALE, Calif., Nov. 29, 2010 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the company's CyberKnife® VSI™ System received the 2010 Minnie for Best New Radiology Device from AuntMinnie.com, the largest and most comprehensive community internet site for radiologists and related professionals in the medical imaging industry. Accuray will be presented with the award at the 2010 Radiological Society of North America (RSNA) annual meeting taking place in Chicago, Ill. from November 28 – December 3, 2010.

"The Minnies awards have been an important barometer of excellence in radiology for the past 11 years," said Brian Casey, editor in chief of AuntMinnie.com. "We're pleased to recognize Accuray's CyberKnife VSI System as the Best New Radiology Device of the year."

Through Accuray's R&D commitment to clinically-driven product enhancements that meet the needs of its customers and improve patient care, the company announced the CyberKnife VSI System in November 2009. The CyberKnife VSI System leverages the versatility, simplicity, and intelligence of the CyberKnife System to broaden the range of treatment options physicians can offer their patients - from radiosurgery to conventionally fractionated Robotic IMRT™.  By supporting this full spectrum of fractionation schemes, the CyberKnife VSI System allows for more customized treatment plans based on patient-specific situations and conditions, such as patients requiring re-irradiation of previously treated areas, or patients requiring partial breast irradiation. Cutting-edge product enhancements, including a world-class 1,000 MU/minute X-band linear accelerator and auto-segmentation capabilities, make planning and delivery simple, convenient and fast for routine clinical use.

"We are honored to receive this designation from such an influential industry publication," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "The team at Accuray is incredibly proud of the CyberKnife VSI System and the benefits it brings to helping patients win their fight against cancer."

About the CyberKnife^® Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 100,000 patients worldwide and currently more than 215 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com. 

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to market acceptance and clinical acceptance are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products, clinical acceptance and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for our 2010 fiscal year, our form 10-Q filed on November 8, 2010 and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

SOURCE Accuray Incorporated